These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12457176)

  • 1. Immunotherapy tackles lupus.
    Kammer GM
    Nat Med; 2002 Dec; 8(12):1356-8. PubMed ID: 12457176
    [No Abstract]   [Full Text] [Related]  

  • 2. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease.
    Sun Y; Chen HM; Subudhi SK; Chen J; Koka R; Chen L; Fu YX
    Nat Med; 2002 Dec; 8(12):1405-13. PubMed ID: 12426559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
    Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
    J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressing the self in rheumatoid arthritis.
    Mittler RS
    Nat Med; 2004 Oct; 10(10):1047-9. PubMed ID: 15459704
    [No Abstract]   [Full Text] [Related]  

  • 6. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
    Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
    Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.
    Tirapu I; Arina A; Mazzolini G; Duarte M; Alfaro C; Feijoo E; Qian C; Chen L; Prieto J; Melero I
    Int J Cancer; 2004 May; 110(1):51-60. PubMed ID: 15054868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.
    Foell J; McCausland M; Burch J; Corriazzi N; Yan XJ; Suwyn C; O'Neil SP; Hoffmann MK; Mittler RS
    Ann N Y Acad Sci; 2003 Apr; 987():230-5. PubMed ID: 12727643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137-mediated immunotherapy for allergic asthma.
    Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
    J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy targeting 4-1BB and its ligand.
    Vinay DS; Kwon BS
    Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
    Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
    Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
    Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
    Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
    Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
    Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
    J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD137: costimulator turns suppressor?
    Al-Shamkhani A
    Immunology; 2004 Sep; 113(1):23-5. PubMed ID: 15312132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.